Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSIP1 | O75475 | 1/20 | 0.52 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.51 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.50 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.50 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.50 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.50 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.50 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.50 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.50 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.50 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.50 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.48 |
| ▸ | MMP3 | P08254 | 2/20 | 0.47 |
| ▸ | MMP8 | P22894 | 2/20 | 0.47 |
| ▸ | MMP13 | P45452 | 2/20 | 0.47 |
| ▸ | MMP1 | P03956 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17266530 | 0.94 | KEAP1 (0.54) | PSIP1KEAP1NFE2L2HDAC1HDAC8 | |
| Hydrochloric Acid SCHEMBL17261315 | 0.92 | KEAP1 (0.53) | PSIP1KEAP1NFE2L2HDAC1HDAC8 | |
| SCHEMBL20329721 | 0.92 | HDAC1 (0.56) | PSIP1KEAP1NFE2L2HDAC1HDAC8 | |
| SCHEMBL1540593 | 0.86 | PSIP1 (0.56) | PSIP1KEAP1NFE2L2HDAC1HDAC8 | |
| SCHEMBL576918 | 0.86 | KEAP1 (0.63) | PSIP1KEAP1NFE2L2HDAC1HDAC8 | |
| SCHEMBL10629823 | 0.86 | PSIP1 (0.61) | PSIP1KEAP1NFE2L2HDAC1HDAC8 | |
| Hydrochloric Acid SCHEMBL1977191 | 0.84 | PSIP1 (0.54) | PSIP1KEAP1NFE2L2HDAC1HDAC8 | |
| SCHEMBL10626503 | 0.84 | HDAC1 (0.65) | PSIP1KEAP1NFE2L2HDAC1HDAC8 | |
| SCHEMBL1546083 | 0.83 | PSIP1 (0.52) | PSIP1KEAP1NFE2L2HDAC1HDAC8 | |
| SCHEMBL777601 | 0.81 | PSIP1 (0.67) | PSIP1KEAP1NFE2L2HDAC1HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12037358-B2 | Compositions comprising reversibly modified oligonucleotides and uses thereof | DICERNA PHARMACEUTICALS, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| CN-117466897-A | Highly selective FGFR2 inhibitors | 深圳福沃药业有限公司 | 2024-01-30 | — | — | CN | disclosed |
| WO-2023202625-A1 | FGFR2 INHIBITOR AND METHOD FOR USING SAME | 深圳福沃药业有限公司 | 2023-10-26 | — | — | WO | disclosed |
| US-11535614-B2 | Dihydropyrrolopyridine inhibitors of ROR-gamma | VITAE PHARMACEUTICALS, LLC (US) | 2022-12-27 | — | — | US | disclosed |
| CN-111393385-B | Synthetic method of benzothiazine formaldehyde derivative | 华南理工大学 | 2022-01-18 | — | — | CN | disclosed |
| US-20210238174-A1 | DIHYDROPYRROLOPYRIDINE INHIBITORS OF ROR-GAMMA | VITAE PHARMACEUTICALS, LLC | 2021-08-05 | — | — | US | disclosed |
| US-10807980-B2 | Dihydropyrrolopyridine inhibitors of ROR-gamma | VITAE PHARMACEUTICALS, LLC (US) | 2020-10-20 | — | — | US | disclosed |
| CN-111393385-A | Synthetic method of benzothiazine formaldehyde derivative | 华南理工大学 | 2020-07-10 | — | — | CN | disclosed |
| US-20200172535-A1 | DIHYDROPYRROLOPYRIDINE INHIBITORS OF ROR-GAMMA | VITAE PHARMACEUTICALS, LLC | 2020-06-04 | — | — | US | disclosed |
| US-10399976-B2 | Dihydropyrrolopyridine inhibitors of ROR-gamma | VITAE PHARMACEUTICALS, LLC (US) | 2019-09-03 | — | — | US | disclosed |
| EP-1625122-A1 | DIPEPTIDYL PEPTIDASE INHIBITORS | Takeda San Diego, Inc. (US) | 2006-02-15 | — | — | EP | disclosed |
| US-20040254226-A1 | Dipeptidyl peptidase inhibitors | SYRRX, INC. | 2004-12-16 | — | — | US | disclosed |
| WO-2004103993-A1 | DIPEPTIDYL PEPTIDASE INHIBITORS | SYRRX, INC. (US) | 2004-12-02 | — | — | WO | disclosed |
| WO-2004103993-A1 | DIPEPTIDYL PEPTIDASE INHIBITORS | SYRRX, INC. (US) | 2004-12-02 | — | — | WO | disclosed |
| EP-0596802-B1 | Erythromycin derivatives, their process of preparation and their application as medicaments | ROUSSEL UCLAF (FR) | 1996-03-20 | — | — | EP | disclosed |
| EP-0596802-A1 | Erythromycin derivatives, their process of preparation and their application as medicaments | ROUSSEL UCLAF (FR) | 1994-05-11 | — | — | EP | disclosed |
| US-4724235-A | N-(arylthioalkyl)-N'-(aminoalkyl)ureas useful in the treatment of arrhythmia | A. H. ROBINS COMPANY, INCORPORATED (US) | 1988-02-09 | — | — | US | disclosed |
| US-4597902-A | TREATMENT OF CARDIAC ARRHYTHMIAS | A. H. ROBINS COMPANY, INCORPORATED (US) | 1986-07-01 | — | — | US | disclosed |
| EP-0066415-B1 | N-(ARYLTHIOALKYL)-N'-(AMINOALKYL)UREAS | A.H. ROBINS COMPANY, INCORPORATED (US) | 1985-10-02 | — | — | EP | disclosed |
| EP-0066415-A2 | N-(arylthioalkyl)-N'-(aminoalkyl)ureas | A.H. ROBINS COMPANY, INCORPORATED (US) | 1982-12-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200172535-A1 | DIHYDROPYRROLOPYRIDINE INHIBITORS OF ROR-GAMMA | RORC, RORB, RORA | PSIP1 2094/4885KEAP1 1021/4885NFE2L2 1011/4885 |
| US-10399976-B2 | Dihydropyrrolopyridine inhibitors of ROR-gamma | RORC, RORB, RORA | PSIP1 1863/4885KEAP1 1224/4885NFE2L2 1232/4885 |
| US-20040254226-A1 | Dipeptidyl peptidase inhibitors | DPP3, DPP4, DPP7 | PSIP1 510/4885KEAP1 3144/4885NFE2L2 4854/4885 |
| US-20210238174-A1 | DIHYDROPYRROLOPYRIDINE INHIBITORS OF ROR-GAMMA | RORC, RORB, RORA | PSIP1 2094/4885KEAP1 1021/4885NFE2L2 1011/4885 |
| US-10807980-B2 | Dihydropyrrolopyridine inhibitors of ROR-gamma | RORC, RORB, RORA | PSIP1 2094/4885KEAP1 1021/4885NFE2L2 1011/4885 |
| US-12037358-B2 | Compositions comprising reversibly modified oligonucleotides and uses thereof | GSS, GSR, RNMT | PSIP1 2092/4885KEAP1 320/4885NFE2L2 1048/4885 |
| US-11535614-B2 | Dihydropyrrolopyridine inhibitors of ROR-gamma | RORC, RORB, RORA | PSIP1 2094/4885KEAP1 1021/4885NFE2L2 1011/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.